Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider Sells $187,780.00 in Stock

Key Points

• Insider Transaction: Arrowhead Pharmaceuticals insider James C. Hamilton sold 9,389 shares at $20.00 each, totaling $187,780, resulting in a 3.46% decrease in their holdings.
• Earnings Report: The company reported a quarterly loss of ($1.26) EPS, missing analysts' expectations, with revenue coming in at $27.77 million, below the estimated $29.01 million.
• Analyst Ratings: Arrowhead Pharmaceuticals has received mixed ratings, with price targets ranging from $17.00 to $60.00 as several analysts reassess their views on the stock.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider James C. Hamilton sold 9,389 shares of the business's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $20.00, for a total value of $187,780.00. Following the completion of the transaction, the insider owned 262,122 shares in the company, valued at $5,242,440. This trade represents a 3.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Arrowhead Pharmaceuticals Price Performance

ARWR stock traded up $1.73 during midday trading on Friday, reaching $20.51. 5,200,816 shares of the company's stock traded hands, compared to its average volume of 1,944,591. The company has a 50-day simple moving average of $16.63 and a two-hundred day simple moving average of $15.94. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $27.34. The company has a market cap of $2.84 billion, a price-to-earnings ratio of -16.02, a PEG ratio of 76.81 and a beta of 0.94. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analyst estimates of $29.01 million. During the same quarter in the prior year, the company earned ($1.38) EPS. On average, analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ARWR shares. Royal Bank Of Canada lowered their price objective on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. B. Riley upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday. Chardan Capital restated a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday. Citigroup decreased their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Finally, Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $43.14.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Teza Capital Management LLC bought a new stake in Arrowhead Pharmaceuticals during the second quarter worth about $300,000. Tidal Investments LLC increased its position in Arrowhead Pharmaceuticals by 82.2% during the second quarter. Tidal Investments LLC now owns 35,775 shares of the biotechnology company's stock worth $565,000 after buying an additional 16,140 shares during the last quarter. Man Group plc increased its position in Arrowhead Pharmaceuticals by 203.8% during the second quarter. Man Group plc now owns 118,782 shares of the biotechnology company's stock worth $1,877,000 after buying an additional 79,683 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Arrowhead Pharmaceuticals during the second quarter worth approximately $91,000. Finally, Hudson Bay Capital Management LP increased its position in Arrowhead Pharmaceuticals by 22.0% during the second quarter. Hudson Bay Capital Management LP now owns 260,000 shares of the biotechnology company's stock worth $4,108,000 after buying an additional 46,870 shares during the last quarter. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.